That is one possibility. Another is that by making motor activity a secondary endpoint, they are collecting data which provides a glimpse into whether 2-73 is worth another trial with motor tremors as a primary endpoint. The cost of gathering that data is minimal. If it does show promise that would be another indication that 2-73 could treat.
Or more likely both possibilities are being explored, both the up side and the down side.
Market Data 
Markets 
AI
